Uncovering the Mechanisms of Metastasis in Fallopian Tube-Originated Ovarian Cancer
揭示输卵管源性卵巢癌的转移机制
基本信息
- 批准号:10419998
- 负责人:
- 金额:$ 44.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-17 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAdhesionsAnimalsAutomobile DrivingBioinformaticsBiologicalBiological AssayCancer PatientCancer cell lineCarcinomaCarcinoma in SituCell AdhesionCell physiologyCellsClinicalDataData SetDevelopmentDiagnosisDiseaseDisease-Free SurvivalDistalEpithelial CellsFamilyFamily memberFundingGenesGeneticGenetic TranscriptionGenetically Engineered MouseGreater sac of peritoneumHumanIn SituIn VitroInduced MutationInterruptionKnowledgeLesionMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMissionModelingMolecularMusMutationNF1 tumor suppressorNeoplasm MetastasisOrganoidsOutcomeOvarian Serous AdenocarcinomaOvaryPathway AnalysisPathway interactionsPatientsPatternPlatinumPopulationPrognosisProteinsRecurrenceResearchResistanceRoleSamplingSerousSourceSystemTP53 geneTestingThe Cancer Genome AtlasTissue StainsTubeTumor Suppressor GenesTumor stageTumor-Associated ProcessUnited States National Institutes of HealthWomanYangantitumor effectapoAI regulatory protein-1brca genecancer cellcancer initiationcancer stem cellcell motilitycell transformationdifferential expressioneffective therapygenetic signatureimprovedin vivoinhibitorinsightintraperitonealknock-downmetastatic processmigrationmouse modelneoplastic cellnew therapeutic targetnovelovarian neoplasmpreventpromoterprostate cancer modelprotein expressionsingle-cell RNA sequencingsmall moleculesmall molecule inhibitortherapeutic targettranscription factortumortumor initiationtumor progression
项目摘要
The vast majority of ovarian cancer patients die from metastatic disease due to lack of effective
treatments. To more successfully treat these women, we urgently need to better understand the
molecular mechanisms of ovarian cancer metastasis. Up to 70% of ovarian cancers are high-grade
serous carcinomas (HGSC). These cancers most commonly initiate from secretory epithelial cells in the
fallopian tube (FT) and are highly metastatic. Genetic alterations, including BRCA and p53 mutations,
facilitate the transformation of FT cells into serous tubal intraepithelial carcinomas as the precursor
lesions of HGSCs. Cells then spread throughout the peritoneal cavity even before the clinically
manifested “primary” ovarian tumors are detected, thus only 15% of patients are diagnosed with more-
curable stage I disease. Very little is known about the molecular and cellular process driving the
formation of disseminated intraperitoneal tumors. Our Ovgp1-iCreER BPRN mouse model recapitulates
the development of precursor lesions from oviduct (equivalent of human FT) and forms metastatic
HGSC, allowing us to explore the process of metastatic tumor development in HGSC. We carried out
single-cell RNA-sequencing of oviducts and tumors from the BPRN mice and identified a population of
tumor-initiating cells (TICs) with an increased ability to produce tumor organoids in vitro and form
metastases in vivo. We validated their presence in human HGSC samples and found their gene
signature to be enriched in 40% of HGSC patient samples in TCGA dataset and associated with poor
prognosis. Using single-cell regulatory networks analysis, we determined that the nuclear receptor
subfamily 2 group F member 2 (NR2F2) pathway was activated in these TICs. On the basis of our
preliminary data and prior research, we hypothesize that NR2F2 pathway is critical for the FT-originated
TICs to drive metastasis in HGSC. We propose three aims to test our hypothesis: 1) Define the
molecular mechanism by which NR2F2 regulates migration and adhesion of ovarian cancer cells; 2)
Characterize the expression and activation pattern of NR2F2 at different stages of tumor development in
the BPRN mouse model. 3) Determine the biological and mechanistic effects of NR2F2 inhibition on
metastasis of HGSC. The proposed study will provide novel insights into mechanisms of HGSC
metastasis and inform the development of new strategies for inhibiting metastasis and prevent their
recurrence in women with HGSC.
绝大多数卵巢癌患者因缺乏有效治疗而死于转移性疾病。
治疗。为了更成功地治疗这些妇女,我们迫切需要更好地了解
卵巢癌转移的分子机制。高达70%的卵巢癌是高级别的
浆液性癌(HGSC)。这些癌症最常见的起源于卵巢癌的分泌上皮细胞。
输卵管(FT)和高度转移性。基因改变,包括BRCA和P53突变,
促进FT细胞向浆液性输卵管上皮内癌转化为前体
HGSCs的病变。然后细胞扩散到整个腹膜腔,甚至在临床上
表现为“原发”的卵巢肿瘤被检测出来,因此只有15%的患者被诊断出患有更多-
可治愈的I期疾病。对分子和细胞过程所知甚少
腹膜内播散性肿瘤的形成。我们的Ovgp1-iCreer BPRN小鼠模型概述
输卵管前驱病变的发生(相当于人输卵管)并形成转移
HGSC,使我们能够探索HGSC中转移肿瘤的发展过程。我们进行了一次
对BPRN小鼠的输卵管和肿瘤进行单细胞RNA测序,并鉴定出一个种群
肿瘤启动细胞(TICs)在体外产生和形成肿瘤有机化合物的能力增强
体内转移。我们证实了它们在人类HGSC样本中的存在,并发现了它们的基因
TCGA数据集中40%的HGSC患者样本中的签名要丰富,并与差相关
预后。利用单细胞调控网络分析,我们确定了核受体
亚家族2组F成员2(NR2F2)通路在这些抽动中被激活。基于我们的
初步数据和以前的研究,我们假设NR2F2通路对FT起源的
TICS可促进HGSC的转移。我们提出了三个目的来检验我们的假设:1)定义
NR2F2调控卵巢癌细胞迁移和黏附的分子机制
肿瘤发生发展不同阶段NR2F2的表达和激活模式
BPRN小鼠模型。3)确定NR2F2抑制作用的生物学和机制效应
HGSC的转移。这项拟议的研究将为HGSC的机制提供新的见解
转移和通知新的策略的发展,以抑制转移和预防其
患有HGSC的妇女的复发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yang Yang-Hartwich其他文献
Yang Yang-Hartwich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yang Yang-Hartwich', 18)}}的其他基金
Uncovering the Mechanisms of Metastasis in Fallopian Tube-Originated Ovarian Cancer
揭示输卵管源性卵巢癌的转移机制
- 批准号:
10649622 - 财政年份:2022
- 资助金额:
$ 44.08万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 44.08万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 44.08万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 44.08万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 44.08万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 44.08万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 44.08万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 44.08万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 44.08万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 44.08万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 44.08万 - 项目类别: